Fernanda Costa Svedman - Search Results

Year	Number of Results
2016	1
2017	1
2018	1
2019	1
2021	2
2022	4
2023	2
2024	0

1

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination.

Arance A, de la Cruz-Merino L, Petrella TM, Jamal R, Ny L, Carneiro A, Berrocal A, Márquez-Rodas I, Spreafico A, Atkinson V, Costa Svedman F, Mant A, Khattak MA, Mihalcioiu C, Jang S, Cowey CL, Smith AD, Hawk N, Chen K, Diede SJ, Krepler C, Long GV. Arance A, et al. Among authors: costa svedman f. J Clin Oncol. 2023 Jan 1;41(1):75-85. doi: 10.1200/JCO.22.00221. Epub 2022 Jul 22. J Clin Oncol. 2023. PMID: 35867951 Clinical Trial.

2

Treatment Patterns and Efficacy of Chemotherapy After Pembrolizumab in Advanced Urothelial Cancer-a Real-World Study in the pre-Antibody-Drug Conjugate Era.

Holmsten K, Eknert J, Öfverholm E, Papantoniou D, Jawdat F, Verbiéné I, Laurell A, Jänes E, Sandzén J, Wojtyna-Dziedzic E, Lagstam I, Söderkvist K, Costa Svedman F, Liedberg F, Bruzelius M, Fransson AS, Kjellström S, Omland LH, Pappot H, Ullén A. Holmsten K, et al. Among authors: costa svedman f. Clin Genitourin Cancer. 2023 Dec;21(6):e438-e448. doi: 10.1016/j.clgc.2023.05.008. Epub 2023 May 17. Clin Genitourin Cancer. 2023. PMID: 37308329 Free article.

3

Stage-specific survival and recurrence in patients with cutaneous malignant melanoma in Europe - a systematic review of the literature.

Svedman FC, Pillas D, Taylor A, Kaur M, Linder R, Hansson J. Svedman FC, et al. Clin Epidemiol. 2016 May 26;8:109-22. doi: 10.2147/CLEP.S99021. eCollection 2016. Clin Epidemiol. 2016. PMID: 27307765 Free PMC article. Review.

4

Dynamics of plasma thymidine kinase activity in metastatic melanoma reflects immune checkpoint inhibitor efficacy.

Costa Svedman F, Jalsenius M, Grozman V, Bergqvist M, Söderdahl F, Rotstein S, Ny L, Egyhazi Brage S, Helgadottir H. Costa Svedman F, et al. Acta Oncol. 2022 Sep;61(9):1116-1120. doi: 10.1080/0284186X.2022.2121615. Epub 2022 Sep 9. Acta Oncol. 2022. PMID: 36083107 No abstract available.

5

Inflammation and Apolipoproteins Are Potential Biomarkers for Stratification of Cutaneous Melanoma Patients for Immunotherapy and Targeted Therapy.

Karlsson MJ, Costa Svedman F, Tebani A, Kotol D, Höiom V, Fagerberg L, Edfors F, Uhlén M, Egyhazi Brage S, Maddalo G. Karlsson MJ, et al. Among authors: costa svedman f. Cancer Res. 2021 May 1;81(9):2545-2555. doi: 10.1158/0008-5472.CAN-20-2000. Epub 2021 Feb 11. Cancer Res. 2021. PMID: 33574091

6

Plasma Thymidine Kinase Activity as a Novel Biomarker in Metastatic Melanoma Patients Treated with Immune Checkpoint Inhibitors.

Costa Svedman F, Jalsenius M, Höiom V, Grozman V, Bergqvist M, Söderdahl F, Eriksson H, Rotstein S, Ny L, Ascierto PA, Brage SE, Helgadottir H. Costa Svedman F, et al. Cancers (Basel). 2022 Jan 29;14(3):702. doi: 10.3390/cancers14030702. Cancers (Basel). 2022. PMID: 35158970 Free PMC article.

7

[Overview of immune-related side effects from immune checkpoint inhibitors. Part 1: Gastrointestinal, lung and kidney toxicity].

Villabona Lisa Villabona L, Costa Svedman F, Jovanovic B, Kaneteg B, Eberhardson M, Magin H, Ullenhag G, Blomqvist L, Helgadottir H. Villabona Lisa Villabona L, et al. Among authors: costa svedman f. Lakartidningen. 2021 Nov 18;118:21115. Lakartidningen. 2021. PMID: 35080767 Free article. Swedish.

8

Proliferation and Immune Response Gene Signatures Associated with Clinical Outcome to Immunotherapy and Targeted Therapy in Metastatic Cutaneous Malignant Melanoma.

Costa Svedman F, Das I, Tuominen R, Darai Ramqvist E, Höiom V, Egyhazi Brage S. Costa Svedman F, et al. Cancers (Basel). 2022 Jul 22;14(15):3587. doi: 10.3390/cancers14153587. Cancers (Basel). 2022. PMID: 35892846 Free PMC article.

9

Extracellular microvesicle microRNAs as predictive biomarkers for targeted therapy in metastastic cutaneous malignant melanoma.

Svedman FC, Lohcharoenkal W, Bottai M, Brage SE, Sonkoly E, Hansson J, Pivarcsi A, Eriksson H. Svedman FC, et al. PLoS One. 2018 Nov 6;13(11):e0206942. doi: 10.1371/journal.pone.0206942. eCollection 2018. PLoS One. 2018. PMID: 30399176 Free PMC article.

10

Combining ERBB family and MET inhibitors is an effective therapeutic strategy in cutaneous malignant melanoma independent of BRAF/NRAS mutation status.

Das I, Wilhelm M, Höiom V, Franco Marquez R, Costa Svedman F, Hansson J, Tuominen R, Egyhàzi Brage S. Das I, et al. Among authors: costa svedman f. Cell Death Dis. 2019 Sep 10;10(9):663. doi: 10.1038/s41419-019-1875-8. Cell Death Dis. 2019. PMID: 31506424 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

11 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

11 results

Results by year